AI drug company raises ₩9.4 trillion in funding
November 20, 2026 · 2 min read
Isomorphic Labs, an AI drug development startup co-founded by Demis Hassabis, has secured ₩9.4 trillion in funding over the past six months. The company announced on November 17 that it raised $5 billion as part of its Series C funding round, following a previous raise of $2.1 billion in May. Isomorphic Labs is aiming to advance its drug candidates into clinical trials using AI-driven design.
The recent funding round was led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz and Alphabet, Google's parent company. Existing investors including GV, CapitalG, Thrive Capital, and Temasek also contributed additional investments.
While the company did not disclose its valuation, it is reportedly discussed under conditions valuing it at $50 billion. The funding will be utilized for the development of its AI drug design engine and to broaden its research scope.
Isomorphic Labs has stated that it is focusing on accelerating its first clinical trials for cancer drug candidates. The company is actively working on over 20 drug development programs and has reported positive preclinical results in oncology and immunology.
The core technology behind Isomorphic Labs is its proprietary AI drug design engine, IsoDDE, which combines various AI models and simulation techniques to predict interactions between proteins and drug candidates, improving the design of suitable molecules for drug development. The company is expanding its research from small molecule drugs to larger biologics.
CEO Hassabis emphasized the ambition to build a platform capable of developing hundreds of new drugs annually. He highlighted that they are focusing on creating technologies and platforms that enable large-scale drug development rather than concentrating on specific drugs or programs.
Despite the substantial funding, Isomorphic Labs has yet to enter clinical trials with its proprietary drug candidates. While it has reported positive outcomes in preclinical studies, it has not provided sufficient specific data. The next challenge will be to prove the effectiveness and safety of its AI-based drug design technology in actual clinical trials following this major investment.